Sanofi will remain disciplined, but still on the lookout for another mid-sized acquisition that can bring value to the French drug maker and further aid its quest to diversify into promising therapy areas, notably oncology and immunology, its chief executive said when presenting the group's third quarter earnings report.
In terms of M&A and its place within the company's strategy to build its portfolio, Brandicourt said, "We were disappointed not to acquire Medivation Inc., but it is not the end of our presence in oncology. When it comes to what is going to be our interest in the future, oncology is still part of it, if we are finding potential targets which make sense strategically and economically.” Analysts’ M&A questions during the Oct. 28 earnings call focused on Sanofi losing out to Pfizer Inc. in the battle for Medivation
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
